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Background: Chronic Obstructive Pulmonary Disease (COPD) is characterized by respiratory and extrarespiratory
components referring both to systemic complications of COPD, like skeletal muscle myopathy, weight loss and others,
and frequently associated comorbidities, interesting various organs and systems (cardiovascular diseases, malignancies,
osteoporosis, diabetes, etc.). These comorbidities may increase the rate of hospitalization of COPD patients and have a
huge effect on the outcomes of the respiratory disease. Inhalation therapy of COPD with bronchodilators and steroid is
primary driven by airflow obstruction, symptoms like dyspnoea, and acute exacerbations. INDACO project has been
developed in 2013 to assess the prevalence and type of comorbidities in COPD patients referred to the outpatient
wards of some hospitals in Central and South Italy and a preliminary report has recently been published. In the present
study, after widening that database, we evaluate the prevalence of comorbidities and the relationships between
comorbidities and sex, age, symptoms, lung function and inhalation therapy in COPD patients.
Methods: In each enrolled patient, anthropometric and anamnestic data, smoking habits, respiratory function, GOLD
(Global initiative for Chronic Obstructive Lung Disease) severity stage, Body Mass Index (BMI), number of acute COPD
exacerbations in previous years, presence and type of comorbidities, and the Charlson Comorbidity Index (CCI) were
recorded.
Results: We collected data of 569 patients (395 males and 174 females, mean age 73 ± 8.5 yrs). The prevalence of
patients with comorbidities was 81.2%. Overall number of comorbidities was not related to airflow obstruction and age,
but to acute exacerbation of COPD, dyspnoea measured with MRC scale, and male gender. A subgroup analysis
revealed that ischaemic heart disease was predominant in males, whereas mood disorders in females. The use of a
more complex (multi-drug) inhalation therapy was related with bronchial obstruction measured by FEV1/FVC (p for
trend = 0.003) and number of comorbidities (p for trend = 0.001). In multivariate analysis, only airflow obstruction and
number of comorbidities were determinant of complexity of therapy, but not MRC and acute exacerbation of COPD.
However, the statistical model reached an extreme low degree of significance (r^2 = 0.07).
Conclusions: Our study showed a high prevalence of comorbidities in COPD, with some differences related to gender.
Number of comorbidities and airflow obstruction represent the determinant of inhalation therapy prescription.
Dyspnoea and acute exacerbation of COPD, unlikely suggested by guidelines, are not significant drivers of therapy in
the real life setting of our study.
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Table 1 Sample distribution by sex
Male Female p
Age (mean ± SD) 73(±8) 73(±9) ns
MRC (mean ± SD) 2.29(±0.9) 2.29(±0.9) ns
BMI (mean ± SD) 27.2 (±5.1) 26.9(±5.3) ns
FEV1% pred. (mean ± SD) 52.9(±19.6) 53.5(±17.7) ns
FEV1/FVC % (mean ± SD) 59.3(±14.9) 60.1(±16.9) ns
COPD exacerbations (mean ± SD) 1.66(±1.09) 1.48(±0.96) 0.057
Charlson index (mean ± SD) 5.1(±2.2) 4.9(±2.2) ns
Comorbidities (mean ± SD) 1.14(±1.2) 0.9(±1.2) 0.03
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Chronic obstructive pulmonary disease (COPD) is an im-
portant cause of morbidity and mortality around the world
and represents a social and economic challenge for na-
tional health systems [1,2]. Airflow limitation, that is not
fully reversible due to airways inflammation and remodel-
ling, and to parenchymal destruction, is the greater cause
of disability and mortality in COPD patients. Moreover,
the presence of comorbidities is related to higher mortal-
ity, overconsumption of drugs and worst quality of life [3].
Several attempts have been made to define an index of
COPD and comorbidities severity, such as BODE [4] and
COTE [5]. However, the relationship between COPD and
comorbidities and inhalation therapy has not been evalu-
ated in real life settings.
In 2013, we published the INDACO project to evaluate
the prevalence of comorbidities in COPD patients referred
to pulmonary units of four major general hospitals in
Rome, and to search correlations between prevalence and
type of comorbidities and patients’ clinical and respiratory
function characteristics [6]. That study analysed 169 pa-
tients. We found a high prevalence of comorbidities in our
population, a significant correlation between some comor-
bidities and COPD and its acute exacerbations, and a sig-
nificant correlation between inhalation therapy, functional
impairment, and a lower prevalence of comorbidities.
This study represents the evolution of the first pilot
study and has the aim to confirm the possible relation-
ship among comorbidities, COPD and respiratory inhal-
ation therapy. We decided to enlarge the observation to
central area of Italy, to avoid bias related to differences
in geographic latitude and in local health system in
Regions far from each others.
Methods
Study design
This is an observational study, carried out as progression
of the INDACO Pilot study, over 12 months of observa-
tion, without a control group, with the engagement of fur-
ther Respiratory Units in a more extended area of Central
and South Italy.
Patients of both sexes, aged more than 40 years and with
a diagnosis of COPD, set by clinical history, respiratory
function tests and radiologic examination, were enrolled
in this study. They were part of the outpatient sample, re-
ferred either for a first examination or for the follow up to
General and University Hospitals and Respiratory Re-
habilitation centers. Patients without respiratory func-
tion test were excluded from the study, both because
they were not able to perform the tests or they had per-
formed them more than one month before. We ex-
cluded from our study also patients with other lung
diseases but without COPD, because of a substantial
difference in respiratory inhalation therapy.Data collection
The same specifically-designed computerized question-
naire, already used and described in the pilot study [6],
was filled in by a respiratory physician for each COPD pa-
tient. Personal and anthropometric data, smoking habit,
clinical history of COPD, number of acute exacerbations in
the previous year, results of spirometry, arterial blood gas
analysis, and 6-minute walking test (6MWT) (performed
during clinical examination or within 3 months), degree of
dyspnea evaluated with the modified Medical Research
Council Dyspnea scale (mMRC), COPD inhalation therapy
and domestic drug regimen, were the collected variables.
For each patient, comorbidities were identified either on
the basis of anamnesis or by drugs use. The Charlson Co-
morbidity Index (CCI) [7] was calculated in a standard way
for each patient. The reported inhalation therapy was
double checked for correctness by the lung physician be-
fore reporting it in the questionnaire. For the analysis of
data, we divided this variable in five classes: 1) “naïve” (no
inhaler therapy), 2) one bronchodilator either a long-acting
beta-adrenergic (LABA) or a long-acting anti-muscarinic
(LAMA), 3) two bronchodilators (LABA plus LAMA)
4) LABA or LAMA and Inhaled Corticosteroids (ICS),
5) LABA plus LAMA plus ICS.
Statistical analysis
We firstly analysed the distribution of parameters of re-
spiratory function, anthropometric characteristics, acute
exacerbations, and comorbidities in relation to gender
and inhalation therapy.
Then, we looked for possible correlations between the
number of acute exacerbations in the previous year and
the level of bronchial obstruction and comorbidities, CCI
score, and inhalation therapy. The five above mentioned
classes of therapy were graduated on the basis of progres-
sively greater complexity. We evaluated distribution of
complexity of inhalation therapy by respiratory function,
anthropometric characteristics and comorbidities. Data
are reported as mean value ± SD (standard deviation from
the mean). The statistical significance was investigated
with the analysis of variance for normally distributed
Figure 1 Prevalence (%) of different comorbidities in a study population of 569 COPD patients. Global prevalence of observed comorbidities.
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Linear regression was used to obtain a significant model
for use of inhalation drugs pursuant to respiratory func-
tion variables, respiratory symptoms, comorbidities, and
acute exacerbations of COPD (AECOPD).
The Ethics Committee of involved hospitals was in-
formed about this observational study, which required a
patients’ informed consent, as usual form of routinely
clinical activities.Results
From 1st September 2009 to 30th August 2013 we enrolled
569 patients, 395 males and 174 females, mean age 73 ±
8.5 years, all affected by COPD. Anthropometric andFigure 2 Values of MRC and COPD exacerbations in relation to the num
COPD in patients with higher prevalence of comorbidities.respiratory function characteristics are summarized in
Table 1, divided by sex (male and female).
Male and female were not different regarding BMI, FEV1,
and MRC. Episodes of exacerbations of COPD tended to
be higher in males than in females, without reaching the
statistical significance (p = 0.057). The prevalence of each
comorbidity is shown in Figure 1. Patients presenting co-
morbidities were 462 (81.2%); out of them 221 patients
(38.8%) had only one comorbidity; 141 (24.8%) had two
comorbidities, and 100 via (17.5%) had 3 or more comor-
bidities. The prevalence of each comorbidity is shown in
Figure 1.
Number of comorbidities was not related to airflow ob-
struction (FEV1/FVC and FEV1% pred) or age; on the con-
trary, statistical differences were observed in frequency ofber of comorbidities. Higher values of MRC and acute exacerbations of





Arterial hypertension 60.8 (±16.1) 57.9 (±14.7) 0.03
Diabetes 64.0 (±15.0) 58.9 (±15.5) 0.01
Ischaemic heart disease 61.2 (±15.5) 59.1 (±15.5) ns
Mood disorders 51.3 (±17.9) 60.1 (±15.3) 0.003
Lung cancer 59.3 (±7.7) 59.6 (±15.7) 0.054
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relation to the number of comorbidities (Figure 2).
The number of comorbidities was different between
males and females: 1.14 ± 1.2 and 0.9 ± 1.2, p = 0.03, re-
spectively. Charlson index was similar in both groups:
5.1 ± 2.2 and 4.9 ± 2.1. Moreover, we observed a signifi-
cant negative correlation between airflow obstruction
and prevalence of arterial hypertension and diabetes.
Conversely, mood disorders were significantly related to
worst respiratory function, while lung cancer was close
to statistical significance. The level of bronchial obstruc-
tion was not different whether ischaemic heart disease
was present or not (Table 2).
Among comorbidities, mood abnormality cases were
significantly more incident among females than males
(8.6% vs 3.8%, RR 0.59, CI 95% 0.40-0.86, p = 0.01). Con-
versely, cardiovascular ischaemic disease was predomin-
ant in males with statistical significance (26.1% vs 18.4%,
RR 1.4, CI 95% 1.0-1.9, p = 0.05). No differences among
males and females were observed in distribution of
hypertension, diabetes, and cancer.
Inhalation therapy was not performed in 107 COPD
patients (18.8%), despite the presence of a respiratory
obstructive damage (mean value of FEV1/FVC = 63.7% ±Figure 3 Mean of comorbidities and COPD acute exacerbations by co
exacerbations of COPD and greater complexity of inhalation therapy.14.4; mean value of FEV1 % of predicted = 54.9% ± 20.3;
mean value of MRC = 2.0 ± 1.1; AECOPD = 1.4 events/
year ± 1.3). The inhalation therapy (graduated as already
specified in increasing order as: naive, one bronchodilator,
two bronchodilators, one bronchodilator plus corticoster-
oid, two bronchodilators plus corticosteroid) with greater
complexity was correlated with the bronchial obstruction
measured by FEV1/FVC and the number of comorbidities,
but not with FEV1%pred, acute exacerbations of COPD,
age, and BMI (Figures 3 and 4).
With linear regression, we observed a reasonable cor-
relation between complexity of inhalation therapy and
MRC, exacerbations of COPD, airflow obstruction and
comorbidities (r^2 = 0.07). In our model, only airflow
obstruction measured by FEV1/FVC and number of co-
morbidities reached statistical significance (Table 3).
Discussion
The frequency of comorbidities in COPD is strictly re-
lated to global population health status. Thus, there are
many differences in the prevalence of comorbidities in
COPD patients, according to geographic area. Based on
this observation and differences between international and
national studies [8,9], we designed the INDACO-project
with the aim to evaluate the relationships between comor-
bidities in Italian COPD patients and respiratory dysfunc-
tion, smoking habits, BMI, and inhalation therapy. In a
pilot project, we previously enrolled and analysed 169 pa-
tients in four general hospitals of Rome [6]. On the basis
of that study, we extended and improved our research out-
side the region and besides hospital settings, involving re-
habilitation and lower intensity care areas.
In the present study, that includes also the cases pre-
viously involved with the same inclusion criteria and
analysis methods, we confirmed a higher prevalence ofmplexity of inhalation therapy. Link between comorbidities, acute
Figure 4 Airflow obstruction and complexity of inhalation therapy. Link between comorbidities and respiratory dysfunction evaluated by
Tiffeneau Index (FEV1/FVC) and FEV1 as percent of predicted.
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national [10] and international data [11]. Updated re-
sults demonstrated that there is no correlation between
number of comorbidities and the obstructive respiratory
dysfunction. Therefore, the higher value of prevalence
might be related to a population bias rather than to de-
gree of airflow obstruction.
Among comorbidities, arterial hypertension showed the
highest prevalence (55.5% ± 4.2). There is a significant dif-
ference between our data and the worldwide prevalence,
as reported by the World Health Organization (WHO),
that ranges in general population from 35% (high income
countries) to 45% (low income countries) [12]. Mannino
et al. [8] reported a global lower prevalence of arterial
hypertension (40.1% ± 0.3) in a similar COPD population.
In that study, the higher prevalence was related to higher
respiratory dysfunction with a 51% rate in GOLD class 3
and 4. On the contrary, our population showed an overall
higher prevalence of arterial hypertension in COPD pa-
tients with higher mean value of FEV1/FVC (Table 2). We
observed the same result in COPD patients with diabetes.
No differences were observed in lung function of COPD
patients with ischaemic heart disease. A similar finding is
reported by Bellocchia et al. [13] who did not find differ-
ences in pressure overload among COPD patients withTable 3 Linear regression model with predictors and
complexity of inhalation therapy as outcome
Coefficient S.E. p
Comorbidities 0.234 0.057 0.000054
FEV1/FVC -0.013 0.004 0.0019
AECOPD 0.044 0.048 ns
MRC -0.008 0.073 nshigher functional impairment. Undoubtedly, a protective ef-
fect of COPD does not exist. Because our study was obser-
vational, it is more likely that patients with more severe
COPD are focused on their respiratory disease instead of
looking after the global health status. The same potential
interpretation could be attributed to the lower value of
FEV1/FVC in COPD patients with mood disorders, where
respiratory dysfunctions drove the state of mind.
Anxiety and depression are frequent in COPD pa-
tients, because lung dysfunction prevents normal phys-
ical activities and social relationships. In the present
investigation prevalence of mood disorders was 5.3%
(±1.9), as reported in other studies when anxiety was
present with or without depression [14,15]. In our study,
the prevalence of this disorder was significantly higher
in females, because of their plausible greater frailty .
We confirm a higher prevalence of diabetes in our
COPD patients (12.5% ± 2.8) than in Italian general
population [16], as previously found in our pilot study
[6]. It is well know that COPD patients have a higher
risk of developing type II diabetes compared to normal
subjects, due to the increase in circulating cytokines, in
particular TNF-α, that interferes with glucose metabol-
ism and insulin sensitivity [17].
We found the prevalence of comorbidities to be related
to acute exacerbations of COPD and dyspnoea measured
by MRC scale, but not with airflow obstruction. As re-
ported by Sievi et al. [18], in COPD patients the limitation
in physical activities is related to comorbidities, also in ab-
sence of FEV1 reduction. We evaluated the use of therapy
with inhalation drugs, dividing the study population in
classes of complexity, as reported in GOLD guidelines [1]
for the choice of therapy: one or two bronchodilators
without or in concomitance with corticosteroids.
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evaluation, showed a moderate airflow obstruction, light
but significant dyspnoea, and more than one acute exacer-
bation of COPD in the previous year. This phenotype rep-
resented almost 20% of the whole sample, meaning that a
significant amount of sick respiratory patients remains un-
treated. Moreover, our study analysed respiratory function
in relation to the use of inhalation drugs. We did not con-
sider the effect of inhalation therapy on respiratory func-
tion, but only the link between therapy and respiratory
conditions.As expected, a more important therapy was re-
lated to a severe respiratory impairment measured by air-
flow obstruction as FEV1/FVC and not as FEV1 alone. No
significant correlation was evident between complexity of
therapy and acute exacerbations of COPD or MRC value.
Instead, a significative correlation was found between ther-
apy and number of comorbidities, but not with Charlson
Index. We suppose that in real life, when obstructive and
restrictive defects frequently coexist, FEV1 itself is not
enough to drive the therapy and it must be complemented
by the FEV1/FVC index.
Conclusions
According to the results of this observational study, the
assessment of comorbidities to evaluate the severity of dis-
ease could be appropriate and useful in real clinical set-
tings where it is mandatory to evaluate the global health
status. However, using the number and the feature of co-
morbidities to drive the inhalation therapy is a still far
practice in medical activity. Further studies are needed,
therefore, to define the role of comorbidities and their fit-
ting treatment in the natural history of COPD.
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